![](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2019\/07\/sensibanner-1024x300-1.jpg\")
<\/p>\nYou might soon find yourself looking for your CBD infused products you were buying at your local drugstore, but they\u2019ve suddenly vanished.<\/p>\n
CBD could soon only be available in pharmacies.\u00a0 \u201cUntil a further update from the EU, consumers, vendors, and manufacturers may find that the sale of CBD oils, supplements and food is disrupted\u201d warns Hanway Associates<\/a>, London based Cannabis Consultants.<\/p>\n At the EIHA16<\/a> much was spoken about the difference between the regulatory framework in the EU compared with Canada, the USA and other countries. The EU is lacking behind! The Novel Food classification of concentrated CBD that the EU published in January 2019 has only added to the confusion and uncertainty. The EIHA is actively lobbying to get the Novel Food classification off the table or at least keep CBD products on the shelves during the registration process. Earlier this year, the EIHA published extensive evidence contradicting the EU\u2019s claim that hemp foods and hemp extracts -including CBD- were not available in Europe before 1997.<\/span><\/p>\n \u00a0<\/p>\n While the rise of CBD<\/a>, \u2018Cannabis Light<\/a>\u2019 and other cannabis-infused products has been going on for a while, it took until this year for the European Union to act regulatory.\u00a0And they\u2019re doing so through the Novel Foods authorization. A term you might not be familiar with and rightfully so. If it weren\u2019t for CBD, you would probably have never heard about it.<\/p>\n Unlike the medicinal cannabis resolution passed by the European Parliament<\/a>, it didn\u2019t come close to getting the same coverage.<\/p>\n\n According to the European Union\u2019s webpage on Novel Foods<\/a>, it is defined as follows:<\/p>\n Novel Food is defined as food that had not been consumed to a significant degree by humans in the EU before 15 May 1997, when the first Regulation on novel food came into force.<\/em><\/p>\n \u2018Novel Food\u2019 can be newly developed, innovative food, food produced using new technologies and production processes, as well as food which is or has been traditionally eaten outside of the EU.<\/em><\/p>\n Examples of Novel Food include new sources of vitamin K (menaquinone) or extracts from existing food (Antarctic Krill oil rich in phospholipids from Euphausia superba), agricultural products from third countries (chia seeds, noni fruit juice), or food derived from new production processes (UV-treated food (milk, bread, mushrooms and yeast).<\/em><\/p>\n The underlying principles underpinning Novel Food in the European Union are that Novel Foods must be:<\/em><\/p>\n \u2013 Safe for consumers<\/em><\/p>\n \u2013 Properly labeled, so as not to mislead consumers<\/em><\/p>\n \u2013 If novel food is intended to replace another food, it must not differ in a way that the consumption of the Novel Food would be nutritionally disadvantageous for the consumer.<\/em><\/p>\n Pre-market authorization of Novel Foods on the basis of an evaluation in line with the above principles is necessary.<\/em><\/p>\n It\u2019s hard to name any other than the examples here and even then, it seems slightly odd to qualify cannabis-derived products as a Novel Food considering it\u2019s long documented use. In fact, there\u2019s a whole searchable Novel Food Catalogue<\/a> on the European Union\u2019s website. Embedded below a previous item we made interviewing the Stanley Brothers on whether CBD should be classified as medicine or food.<\/p>\n\n \u00a0<\/p>\n Before a product can be legally market in the EU, Novel Foods are required to have a pre-market safety assessment and authorization under the Novel Foods Regulation (Regulation (EU) No 2015\/2283<\/a>. Meanwhile, several European countries now allow low THC \u2018cannabis light<\/a>\u2018 as we\u2019ve reported on below.<\/p>\n\n We asked August de Loor<\/a>, drugs expert and chairman of the Cannabino\u00efden Adviesbureau Nederland<\/a> (Cannabinoid Advisory Bureau Netherlands) a couple of questions.<\/p>\n CNN: Hi, thanks for doing this. Could you introduce yourself first?<\/strong><\/p>\n AUGUST:<\/strong> I\u2019m August de Loor, chairman of CAN (Cannabino\u00efden Adviesbureau Nederland), a platform for the gathering of knowledge and insights about everything related to cannabinoids. This knowledge and insights are available to everybody who is interested. On top of that, CAN has been an interlocutor with multiple authorities and governments to realize effective policy considering the many positive applications of cannabinoids. The board and members consist of people varying from all parts of the cannabis industry chain, in addition to lawyers, pharmacologists, pioneers from the very beginning, to mainstream companies such as drugstore chains.<\/p>\n CNN: These new regulations seem to have come out of nowhere, how come? Or why not?<\/strong><\/p>\n AUGUST:<\/strong> The novel food regulation certainly does not come out of the blue. In recent years much has been done to downplay the (so-called wonder) effects of cannabinoids, of contaminated oils, lack of clarity about the composition of the oils (including many overlaps of THC containing oils and pure CBD), of negative perception, politics, media, authorities and authorities about cannabinoids because it is associated with the world of drugs, the cannabis trade, cold water fears in primary health care and mental health care to get started with cannabis products. And all of that within the many European countries.<\/p>\n CNN: What does this mean for the current European CBD market?<\/strong><\/p>\n AUGUST:<\/strong> The Novel Food Catalogue process can be positively inserted as an instrument of the cannabinoids. So they\u2019re not to be classified under either strict drug laws or pharma regulations but remain as a commodity. The consequence of the Novel Food trajectory is that research is necessary to find out cannabinoids like CBD are (or are not) harmful to health. During this investigation, CBD should be withdrawn (read: should not be sold). And the latter is in many ways an extremely undesirable situation that CAN wants to avoid in all possible ways through consultation with governments, politicians, publicity, cooperation with sister organizations etc.<\/p>\n CNN: Is there anything you would like to add?<\/strong><\/p>\n AUGUST:<\/strong> There\u2019s every reason to work together to ensure that all parties involved work towards a quality mark for CBD oils, which could also be applied to oils with THC. And working towards the legalization of cannabis for recreational use including allowing home-grown cannabis and stopping the witch hunt of house evictions etc.<\/p>\n It\u2019s time to start with this three-step strategy of recognizing the diverse uses of cannabis, not forgetting the fourth aspect of the many beautiful products you can make with this plant!<\/p>\n August also has his own website, augustdeloor.nl<\/a> and can be found on Twitter: @augustdeloor<\/a>.<\/em><\/p>\n After the recent passage of the 2018 Farm Bill<\/a> and the federal legalization of industrial hemp<\/a>, this week the U.S. Department of Agriculture (USDA) responded to prospective hemp farmers<\/a>. Furthermore, in the same week, the Federal Drug Agency (FDA) head revealed new details about plans to \u201cpursue alternative pathways for CBD regulation<\/a>\u201d. Embedded below Doug Fine reporting recently from Hawaii.<\/p>\n\n \u201cIt\u2019s going to be a challenge,\u201d said Bob Hoban when asked about this shift of the Departments shift. Robert (Bob) Hoban<\/a> is one of the leading lawyers in the cannabis and hemp industry. He has worked as a cannabis policy professor at the University of Denver, where he taught cannabis policy courses in Colorado and across the globe. We got to interview Bob at the FAAAT conference<\/a> in December last year.<\/p>\n\n \u201cWill it be food? A supplement? A functional food? Medicinal food? That\u2019s the different patterns we\u2019re looking at\u201d Bob Hoban said to us in a later interview.<\/p>\n GW Pharmaceuticals recently managed to get the FDA to approve its cannabis-derived product<\/a>, now the first federally legal prescription drug.<\/p>\n \u201cPresume I found a berry in a far away rain forest. Nobody used that berry before and I brought it back with me to the United States. And I wanted to make that berry in a drug to treat your specific condition\u2026 If I inked that application with that berry with the FDA before that berry was sold over the country as a naturally occurring product, then the drug gets to use that product, not the retailers. So if CBD had to be sold as a supplement or as a food product before GW put in their application in for Epidolex (GW\u2019s approved drug), that is the technical reading of the Food, Drug, and Cosmetic Act<\/a>.\u201d Bob furthermore states.<\/p>\n On a positive note, Bob concludes: \u201cConsidering there are hundreds of billions of dollars already in a US based economy, infrastructure including warehouses and production facilities and consumer demand, I just think it\u2019s too big to fail right now\u201d<\/p>\n The post CBD products in the EU could soon only be available in pharmacies. Is it too late to change?<\/a> appeared first on Cannabis News Network<\/a>. – Also, download the free app in your app store – Cannabis News Network<\/p>\nWhat are Novel Foods?<\/h2>\n
How does this affect current CBD products?<\/h2>\n
And in the US?<\/h2>\n
![\"Sensi](\"https:\/\/cannabiscultivatornews.com\/home\/wp-content\/uploads\/2019\/07\/sensibanner-1024x300.jpg\")
<\/a><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n